However, the hypnozoiticidal efficacy of current drugs like primaquine and tafenoquine cannot be directly assessed due to the undetectable nature of hypnozoites. Researchers conducted a retrospective ...

cGlobal and Tropical Health Division, Menzies School of Health Research and Charles Darwin University, Darwin, NT, Australia dCentre for Tropical Medicine and Global Health, Nuffield Department of ...

“The promise shown by tafenoquine in treating relapsing babesiosis can certainly give patients and physicians reason for hope and optimism,” said Geoff Dow, PhD, chief executive officer of 60 ...

(NASDAQ: SXTP; SXTPW) (“60 Degrees Pharmaceuticals” or the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today that the first patient has ...

(SXTPW), a pharmaceutical company specializing in infectious disease treatments, on Wednesday announced the expansion of its clinical trial for tafenoquine, a potential treatment for babesiosis ...

announced the enrollment of the first patient in an expanded access study (NCT06478641) assessing the effectiveness of tafenoquine in treating patients with persistent babesiosis, particularly ...

60 Degrees Pharmaceuticals (SXTP) announced that the first patient has been enrolled in NCT06478641, an expanded access clinical study intended to confirm the activity of tafenoquine in treating ...

“The Tafenoquine for Babesiosis Expanded Access clinical study may strengthen that hope in a patient population that has few treatment options today. We are pleased to be leading the way in ...